PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia

Nature Medicine

Volumn 9, Issue 11, 2003, Pages 1413-1417

  Padua, Rose Ann ^a,b   Larghero, Jerome ^a   Robin, Marie ^a   Le Pogam, Carol ^a   Schlageter, Marie Helene ^a   Muszlak, Sacha ^b   Fric, Jan ^a   West, Robert ^c   Rousselot, Philippe ^a   Phan, Thi Hai ^a   Mudde, Liesbeth ^a   Teisserenc, Helene ^a   Carpentier, Antoine F ^a   Kogan, Scott ^d   Degos, Laurent ^a   Pla, Marika ^a   Bishop, J Michael ^d   Stevenson, Freda ^e   Charron, Dominique ^a   Chomienne, Christine ^a  

^a INSERM   (France)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; ONCOPROTEIN; PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TETANUS FRAGMENT C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; IMMUNE RESPONSE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; DISEASE MODELS, ANIMAL; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; TRETINOIN; VACCINES, DNA;

ANIMALIA;

EID: 0345538675     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm949     Document Type: Article

References (30)

1. Wolff, J.A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465-1468 (1990).
2. Stevenson, F.K. et al. Idiotypic DNA vaccines against B-cell lymphoma. Immunol. Rev. 145, 211-228 (1995).
3. Syrengelas, A.D., Chen, T.T. & Levy, R. DNA immunization induces protective immunity against B-cell lymphoma. Nat. Med. 2, 1038-1041 (1996).
4. King, C.A. et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. 4, 1281-1286 (1998).
5. Spellerberg, M. B. et al. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J. Immunol. 159, 1885-1892 (1997).
6. Brown, D. et al. A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 94, 2551-2556 (1997).
7. Lallemand-Breitenbach, V. et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189, 1043-52 (1999).
8. Kogan, S.C., Hong, S.H., Shultz, D.B., Privalsky, M.L. & Bishop, J.M. Leukemia initiated by PMLRARα: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood 95, 1541-1550 (2000).
9. + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol. 26, 2671-2679 (1996).
10. Rice, J., Elliott, T., Buchan, S. & Stevenson, F.K. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs; implications for cancer vaccines. J. Immunol. 167, 1558-1565 (2001).
11. Chen, S.A. et al. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine. Clin. Cancer Res. 6, 4381-4388 (2000).
12. Westervelt, P. et al. Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia, Proc. Natl. Acad. Sci. USA 99, 9468-9473 (2002).
13. Dermime, S. et al. Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-α hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin. Cancer Res. 2, 593-600 (1996).
14. Gambacorti-Passerini, C. et al. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/ RAR α present in acute promyelocytic leukemia cells. Blood 81, 1369-1375 (1993).
15. Finn, O.J. & Forni, G. Prophylactic cancer vaccines. Curr. Opin. Immunol. 14, 172-177 (2002).
16. Forni, G., Lollini, P.L., Musiani, P. & Colombo, M.P. Immunoprevention of cancer: is the time ripe? Cancer Res. 60, 2571-2575 (2000).
17. Hu, J. et al. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 177, 1681-1690 (1993).
18. Lufkin, T. et al. High postnatal lethality and testis degeneration in retinoic acid receptor α mutant mice. Proc. Natl. Acad. Sci. USA 90, 7225-7229 (1993).
19. Mark, M. et al. A genetic dissection of the retinoid signalling pathway in the mouse. Proc. Nutr. Soc. 58, 609-613 (1999).
20. Dresser, D.W. Adjuvanticity of vitamin A. Nature 217, 527-529 (1968).
21. Zhu, J. et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor α (RARα) and oncogenic RARα fusion proteins. Proc. Natl. Acad. Sci. USA 96, 14807-14812 (1999).
22. Stephensen, C.B. et al. Vitamin A enhances in vitro Th2 development via retinoid X receptor pathway. J. Immunol. 168, 4495-4503 (2002).
23. McConkey, S.J. et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans, Nat. Med. 9, 729-735 (2003).
24. Krieg, A.M. CpG motifs: the active ingredient in bacterial extracts? Nat. Med. 9, 831-835 (2003).
25. Cassinat, B. et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 14, 324-328 (2000).
26. Sambrook, J., Fritsch, E.F. & Maniatis, T. Plasmid vectors. in Molecular Cloning. A Laboratory Manual, 1.33-1.52 (Cold Spring Harbor Laboratory Press, New York, 1989).
27. de The, H. et al. The PML-RAR α fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR, Cell 66, 675-684 (1991).
28. Delva, L. et al. Physical and functional interactions between cellular retinoic acid binding protein II and the retinoic acid-dependent nuclear complex. Mol. Cell. Biol. 19, 7158-7167 (1999).
29. Parrado, A. et al. Retinoic acid receptor α1 variants, RARα1δBC, and RARα1δBC, define a new class of nuclear receptor isoforms. Nucleic Acids Res. 29, 4901-4908 (2001).
30. Lust, J.A., Kumar, V., Burton, R.C., Bartlett, S.P. & Bennett, M. Heterogeneity of natural killer cells in the mouse. J. Exp. Med. 154, 306-317 (1981).